Clinical Trial Update: Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial update on SHR-1819 injection for moderate to severe atopic dermatitis assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• SHR-1819

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Moderate to Severe Atopic Dermatitis | Phase 2 | Status: COMPLETED